# Insights on Ilika’s 2024 results and future milestones (LON:IKA)

- Link: https://www.directorstalkinterviews.com/insights-on-ilika%e2%80%99s-2024-results-and-future-milestones-lonika/4121165885
- Published: 2024-07-24T14:30:23+01:00
- Author: Amilia Stone

**[Ilika plc](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)**(
[LON:IKA](https://www.directorstalkinterviews.com/company/ilika-plc/ika.l)) is the
topic of conversation when **Baden Hill Partners**’ Clean-Tech Equities Specialist
Dr Tom McColm caught up with DirectorsTalk for an exclusive interview.

**Q1: Tom, Ilika have announced their results for 2024. What did you make of them?**

**A1**: The numbers were as expected, maybe a little bit more grant revenue than
normal that kept the cash burn down a bit, but really the numbers at the moment 
aren’t the most important thing.

What was very interesting was the progress that’s been delivered in the period and
post-period on both the Stereax and particularly the Goliath side of the business.

**Q2: So, if we look at the Goliath side then first, what milestones were delivered
in and post-period and why were they important?**

**A2**: Goliath is the solid-state battery cells for EVs, as you know, the bigger
batteries that Ilika are doing. In the period, they hit what’s called a D4 design
freeze, quite an important point where they froze the design, where they reached
the level of performance that hit that, and then they turned that into a P1 prototype
of that D4 design. So that was quite a landmark on the whole commercialisation journey.

Just shortly after that, at cell level, the pouch cell, they achieved energy density
parity with incumbent lithium-ion EV batteries. Now that’s, it’s a bit of a symbolic
thing, but that’s only going to get better, as they evolve. It means that their 
batteries will get more energy into a smaller space and that’s on top of the inherent
safety and system advantages that solid-state batteries bring. That’s why everyone
chases after them.

Post-period, probably the most important and relevant thing was that the P1 prototypes
have been getting shipped to a couple of their tier one automotive customers for
testing.

One of those customers, the testing and evaluation is being conducted in-house at
Ilika, but the other they’re conducting it themselves. So, they have actually got
EV solid-state batteries into customer hands for testing on their own sites, which
is quite a landmark.

**Q3: What progress was made on the micro format, the Stereax program? Y**

**A3**: Stereax program, it’s probably a little bit ahead in terms of getting to
revenue. First batches of Stereax M300 were shipped to customers for evaluation 
from the UK facility.

In the period, they, I think we covered this interim, but very good news that they
agreed and entered into a 10-year licensing and technology transfer agreement with
US MedTech partner, Cirtec, because Stereax’s is by far most value-add markets are
in these medical device applications, of which Cirtec are a very decently sized 
player in the US

They also executed the equipment, the production equipment transfer installation,
and they’re pretty much through the commissioning phase of that, so that Cirtec 
can start producing IKA’s batteries in the States at scale and then ramp that up.

So again, to emphasise, I think the key thing in both sides of the business in this
period, they have got their battery technology out of their labs and into real customer
hands for testing and evaluation, which is a good development.

**Q4: With that in mind then, what should investors and potential investors be looking
out for from Ilika over the next 12 months?**

**A4**: On the Stereax side, completion of the Cirtec Stereax production commissioning,
and then more shipments of Stereax, batches of Stereax to their customers, I think
they’ve got 21 customers via Cirtec that they’re engaging with, so more shipments
to those customers, potentially more customers coming online via Cirtec, and possibly,
mid- where are we now. So if we go into mid-‘25, some early Stereax revenues, both
from the bit that Ilika makes in-house and from Cirtec selling the devices themselves.

On the Goliath side, just more of the same, further customer trials and evaluation
and more progress, like I said, they hit the D4, P1, the next big step on that journey
is, I think, the D8 and the second prototyping stage. They’re going to be moving
towards that and hopefully achieve that on their journey towards the minimum viable
product in that market.

Once you’re up at those levels then the commercial conversations get very interesting,
so that’s what people should be looking out for.

Share on:
